Abstract
The susceptibilities of 120 clinical isolates of Brucella melitensis and 3 reference strains of the same species to six fluoroquinolones (clinafloxacin, PD 117596, PD 131628, PD 138312, PD 140248, and ciprofloxacin) were examined by agar dilution MIC methodology. Clinafloxacin was the most active compound tested (MIC at which 50% of strains tested were inhibited [MIC50] and MIC90 of 0.06 micrograms/ml). Its level of activity was slightly higher than that of PD 117596 (MIC50 and MIC90 of 0.12 micrograms/ml). PD 131628 and ciprofloxacin were less active than clinafloxacin, with MIC50s ranging from 0.12 to 0.25 micrograms/ml and MIC90s of between 0.25 and 0.5 micrograms/ml for the two compounds. The activity levels of PD 138312 and PD 140248, with MIC50s ranging from 1 to 2 micrograms/ml and MIC90s of 4 to 8 micrograms/ml, were lower than those of the other fluoroquinolones tested.
Full Text
The Full Text of this article is available as a PDF (157.9 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Acocella G., Bertrand A., Beytout J., Durrande J. B., Garcia Rodriguez J. A., Kosmidis J., Micoud M., Rey M., Rodriguez Zapata M., Roux J. Comparison of three different regimens in the treatment of acute brucellosis: a multicenter multinational study. J Antimicrob Chemother. 1989 Mar;23(3):433–439. doi: 10.1093/jac/23.3.433. [DOI] [PubMed] [Google Scholar]
- Domagala J. M. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother. 1994 Apr;33(4):685–706. doi: 10.1093/jac/33.4.685. [DOI] [PubMed] [Google Scholar]
- Easmon C. S., Crane J. P., Blowers A. Effect of ciprofloxacin on intracellular organisms: in-vitro and in-vivo studies. J Antimicrob Chemother. 1986 Nov;18 (Suppl 500):43–48. doi: 10.1093/jac/18.supplement_d.43. [DOI] [PubMed] [Google Scholar]
- García-Rodriguez J. A., García Sánchez J. E., Trujillano I. Lack of effective bactericidal activity of new quinolones against Brucella spp. Antimicrob Agents Chemother. 1991 Apr;35(4):756–759. doi: 10.1128/aac.35.4.756. [DOI] [PMC free article] [PubMed] [Google Scholar]
- García-Rodríguez J. A., García-Sánchez J. E., Trujillano-Martín I., García-Sánchez E., García-García M. I., Fresnadillo M. J. Activity of BAY y 3118, a novel 4-quinolone, against Brucella melitensis. J Chemother. 1994 Apr;6(2):102–106. doi: 10.1080/1120009x.1994.11741137. [DOI] [PubMed] [Google Scholar]
- Pankuch G. A., Jacobs M. R., Appelbaum P. C. Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin. Antimicrob Agents Chemother. 1994 Feb;38(2):369–370. doi: 10.1128/aac.38.2.369. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Qadri S. M., Ayub A., Ueno Y., Saldin H. Susceptibility of Salmonella typhi and Brucella melitensis to the new fluoroquinolone rufloxacin (MF 934). Chemotherapy. 1993 Sep-Oct;39(5):311–314. doi: 10.1159/000239142. [DOI] [PubMed] [Google Scholar]
- al-Sibai M. B., Qadri S. M. Development of ciprofloxacin resistance in Brucella melitensis. J Antimicrob Chemother. 1990 Feb;25(2):302–303. doi: 10.1093/jac/25.2.302. [DOI] [PubMed] [Google Scholar]